Peter Zage

Title(s)Associate Professor In Residence, Pediatrics
SchoolVc-health Sciences-schools
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    Children's Memorial Hospital, Chicago, IL2005Pediatric Hematology/Oncology
    University of Chicago Children's Hospital, Chicago, IL2002Pediatrics
    The Johns Hopkins University, Baltimore, MDBA1990Biology
    Columbia University College of Physicians & Surgeons, New York, NYMD, PhD1999Cell Biology

    Collapse Overview 
    Collapse Overview
    There is a critical need for new treatment options for children with relapsed and refractory solid tumors, and therapies directed against biologically relevant pathways are likely to be more effective with less toxicity. The goals of my clinical and translational research are to develop novel treatments and identify novel targets for therapies for children with solid tumors, in order to improve outcomes and to reduce the incidence and severity of the long-term side effects of current therapy. My primary laboratory projects include studies to better understand the pathways involved in the regulation of growth factor receptor trafficking and degradation in tumor cells and their role in tumor growth and treatment response in addition to studies to identify novel therapeutic targets and novel agents synergistic with established therapies.
    We have identified several promising novel targeted agents that are effective against pediatric solid tumors, and we have translated many of these therapies into early phase clinical trials for children with relapsed and refractory solid tumors. We have also identified a number of pathways required for neuroblastoma tumor cell survival, and these studies are likely to identify treatment combinations using readily available drugs that can also be rapidly tested in clinical trials, leading to improved treatments, reduced relapse rates, and improved survival for children with all forms of cancer.
    Our continued research looks to build on these findings through a better understanding of growth factor receptor trafficking and its link to chemotherapy responses and resistance to targeted therapies and through direct targeting of receptor trafficking as a unique approach to pediatric solid tumor therapy.
    Collapse Websites

    Collapse Research 
    Collapse Research Activities and Funding
    The Role of Growth Factor Receptor Trafficking in Tumorigenesis
    NIH R01CA166749Apr 5, 2013 - Sep 30, 2018
    Role: Principal Investigator

    Collapse ORNG Applications 
    Collapse Clinical Trials
    Collapse Featured Publications

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. UBE4B interacts with the ITCH E3 ubiquitin ligase to induce Ku70 and c-FLIPL polyubiquitination and enhanced neuroblastoma apoptosis. Cell Death Dis. 2023 11 13; 14(11):739. Le Clorennec C, Subramonian D, Huo Y, Zage PE. PMID: 37957138; PMCID: PMC10643674.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    2. Eflornithine as Postimmunotherapy Maintenance in High-Risk Neuroblastoma: Externally Controlled, Propensity Score-Matched Survival Outcome Comparisons. J Clin Oncol. 2024 Jan 01; 42(1):90-102. Oesterheld J, Ferguson W, Kraveka JM, Bergendahl G, Clinch T, Lorenzi E, Berry D, Wada RK, Isakoff MS, Eslin DE, Brown VI, Roberts W, Zage P, Harrod VL, Mitchell DS, Hanson D, Saulnier Sholler GL. PMID: 37883734; PMCID: PMC10730038.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCTClinical Trials
    3. USP7 Inhibition Suppresses Neuroblastoma Growth via Induction of p53-Mediated Apoptosis and EZH2 and N-Myc Downregulation. Int J Mol Sci. 2023 Sep 07; 24(18). Le Clorennec C, Lee K, Huo Y, Zage PE. PMID: 37762082; PMCID: PMC10531325.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    4. Targeting the RET tyrosine kinase in neuroblastoma: A review and application of a novel selective drug design strategy. Biochem Pharmacol. 2023 10; 216:115751. Steen EA, Basilaia M, Kim W, Getz T, Gustafson JL, Zage PE. PMID: 37595672; PMCID: PMC10911250.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    5. A phase II trial of nifurtimox combined with topotecan and cyclophosphamide for refractory or relapsed neuroblastoma and medulloblastoma. Int J Cancer. 2023 Sep 01; 153(5):1026-1034. Eslin D, Zage PE, Bergendahl G, Lewis E, Roberts W, Kraveka J, Mitchell D, Isakoff MS, Rawwas J, Wada RK, Fluchel M, Brown VI, Ginn K, Higgins T, BeeravallyNagulapally A, Dykema K, Hanna G, Ferguson W, Saulnier Sholler GL. PMID: 37246577.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCTClinical Trials
    6. Identification of a novel gene signature for neuroblastoma differentiation using a Boolean implication network. Genes Chromosomes Cancer. 2023 06; 62(6):313-331. Zage PE, Huo Y, Subramonian D, Le Clorennec C, Ghosh P, Sahoo D. PMID: 36680522; PMCID: PMC10257350.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    7. Allele-specific expression reveals genes with recurrent cis-regulatory alterations in high-risk neuroblastoma. Genome Biol. 2022 03 04; 23(1):71. Sen A, Huo Y, Elster J, Zage PE, McVicker G. PMID: 35246212; PMCID: PMC8896304.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    8. Genomic and Transcriptomic Analysis of Relapsed and Refractory Childhood Solid Tumors Reveals a Diverse Molecular Landscape and Mechanisms of Immune Evasion. Cancer Res. 2021 12 01; 81(23):5818-5832. Byron SA, Hendricks WPD, Nagulapally AB, Kraveka JM, Ferguson WS, Brown VI, Eslin DE, Mitchell D, Cornelius A, Roberts W, Isakoff MS, Oesterheld JE, Wada RK, Rawwas J, Neville K, Zage PE, Harrod VL, Bergendahl G, VanSickle E, Dykema K, Bond J, Chou HC, Wei JS, Wen X, Reardon HV, Roos A, Nasser S, Izatt T, Enriquez D, Hegde AM, Cisneros F, Christofferson A, Turner B, Szelinger S, Keats JJ, Halperin RF, Khan J, Saulnier Sholler GL, Trent JM. PMID: 34610968; PMCID: PMC10240575.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCells
    9. The Anti-Tumor Activity of the NEDD8 Inhibitor Pevonedistat in Neuroblastoma. Int J Mol Sci. 2021 Jun 18; 22(12). Foster JH, Barbieri E, Zhang L, Scorsone KA, Moreno-Smith M, Zage P, Horton TM. PMID: 34207315; PMCID: PMC8234433.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansAnimalsCells
    10. Overview and recent advances in the targeting of medulloblastoma cancer stem cells. Expert Rev Anticancer Ther. 2021 09; 21(9):957-974. Paul MR, Zage PE. PMID: 34047251.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCells
    11. Is high-risk neuroblastoma induction chemotherapy possible without G-CSF? A pilot study of safety and treatment delays in the absence of primary prophylactic hematopoietic growth factors. Pediatr Blood Cancer. 2020 10; 67(10):e28417. Whittle SB, Smith V, Silverstein A, Parmeter M, Minard CG, Bernhardt MB, Zage PE, Venkatramani R, Nuchtern JG, Heczey A, Russell HV, Shohet JM, Foster JH. PMID: 32729196; PMCID: PMC7722106.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCTClinical Trials
    12. Regorafenib is effective against neuroblastoma in vitro and in vivo and inhibits the RAS/MAPK, PI3K/Akt/mTOR and Fos/Jun pathways. Br J Cancer. 2020 08; 123(4):568-579. Subramonian D, Phanhthilath N, Rinehardt H, Flynn S, Huo Y, Zhang J, Messer K, Mo Q, Huang S, Lesperance J, Zage PE. PMID: 32457362; PMCID: PMC7434894.
      View in: PubMed   Mentions: 22     Fields:    Translation:HumansAnimalsCells
    13. Characterization of G-CSF receptor expression in medulloblastoma. Neurooncol Adv. 2020 Jan-Dec; 2(1):vdaa062. Paul MR, Huo Y, Liu A, Lesperance J, Garancher A, Wechsler-Reya RJ, Zage PE. PMID: 32642714; PMCID: PMC7316203.
      View in: PubMed   Mentions: 5  
    14. A subset analysis of a phase II trial evaluating the use of DFMO as maintenance therapy for high-risk neuroblastoma. Int J Cancer. 2020 12 01; 147(11):3152-3159. Lewis EC, Kraveka JM, Ferguson W, Eslin D, Brown VI, Bergendahl G, Roberts W, Wada RK, Oesterheld J, Mitchell D, Foley J, Zage P, Rawwas J, Rich M, Lorenzi E, Broglio K, Berry D, Saulnier Sholler GL. PMID: 32391579; PMCID: PMC7586843.
      View in: PubMed   Mentions: 22     Fields:    Translation:HumansCTClinical Trials
    15. Mechanisms of Efficacy of the FGFR1-3 Inhibitor AZD4547 in Pediatric Solid Tumor Models. Invest New Drugs. 2020 12; 38(6):1677-1686. Phanhthilath N, Hakim S, Su C, Liu A, Subramonian D, Lesperance J, Zage PE. PMID: 32436058.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCells
    16. The Potential Functional Roles of NME1 Histidine Kinase Activity in Neuroblastoma Pathogenesis. Int J Mol Sci. 2020 May 07; 21(9). Adam K, Lesperance J, Hunter T, Zage PE. PMID: 32392889; PMCID: PMC7247550.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansAnimalsCells
    17. Sociodemographic and clinical characteristics associated with vitamin D status in newly diagnosed pediatric cancer patients. Pediatr Hematol Oncol. 2020 May; 37(4):314-325. Aristizabal P, Sherer M, Perdomo BP, Castelao E, Thornburg CD, Proudfoot J, Jacobs E, Newfield RS, Zage P, Roberts W, Martinez ME. PMID: 32153233; PMCID: PMC7207243.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCTClinical Trials
    18. The multikinase inhibitor RXDX-105 is effective against neuroblastoma in vitro and in vivo. Oncotarget. 2019 Oct 29; 10(59):6323-6333. Flynn SM, Lesperance J, Macias A, Phanhthilath N, Paul MR, Kim JW, Tamayo P, Zage PE. PMID: 31695841; PMCID: PMC6824878.
      View in: PubMed   Mentions: 8     Fields:    
    19. Novel Therapies for Relapsed and Refractory Neuroblastoma. Children (Basel). 2018 Oct 31; 5(11). Zage PE. PMID: 30384486; PMCID: PMC6262328.
      View in: PubMed   Mentions: 28  
    20. Maintenance DFMO Increases Survival in High Risk Neuroblastoma. Sci Rep. 2018 09 27; 8(1):14445. Sholler GLS, Ferguson W, Bergendahl G, Bond JP, Neville K, Eslin D, Brown V, Roberts W, Wada RK, Oesterheld J, Mitchell D, Foley J, Parikh NS, Eshun F, Zage P, Rawwas J, Sencer S, Pankiewicz D, Quinn M, Rich M, Junewick J, Kraveka JM. PMID: 30262852; PMCID: PMC6160434.
      View in: PubMed   Mentions: 41     Fields:    Translation:HumansCTClinical Trials
    21. Overview and recent advances in the treatment of neuroblastoma. Expert Rev Anticancer Ther. 2017 Apr; 17(4):369-386. Whittle SB, Smith V, Doherty E, Zhao S, McCarty S, Zage PE. PMID: 28142287.
      View in: PubMed   Mentions: 162     Fields:    Translation:Humans
    22. The novel kinase inhibitor ponatinib is an effective anti-angiogenic agent against neuroblastoma. Invest New Drugs. 2016 12; 34(6):685-692. Whittle SB, Patel K, Zhang L, Woodfield SE, Du M, Smith V, Zage PE. PMID: 27586230.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansAnimalsCells
    23. CD114: A New Member of the Neural Crest-Derived Cancer Stem Cell Marker Family. J Cell Biochem. 2017 02; 118(2):221-231. Zage PE, Whittle SB, Shohet JM. PMID: 27428599.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansAnimalsCells
    24. Nifurtimox Is Effective Against Neural Tumor Cells and Is Synergistic with Buthionine Sulfoximine. Sci Rep. 2016 06 10; 6:27458. Du M, Zhang L, Scorsone KA, Woodfield SE, Zage PE. PMID: 27282514; PMCID: PMC4901277.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCells
    25. A Polymorphism in the FGFR4 Gene Is Associated With Risk of Neuroblastoma and Altered Receptor Degradation. J Pediatr Hematol Oncol. 2016 Mar; 38(2):131-8. Whittle SB, Reyes S, Du M, Gireud M, Zhang L, Woodfield SE, Ittmann M, Scheurer ME, Bean AJ, Zage PE. PMID: 26840079; PMCID: PMC4758892.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    26. Binimetinib inhibits MEK and is effective against neuroblastoma tumor cells with low NF1 expression. BMC Cancer. 2016 Mar 01; 16:172. Woodfield SE, Zhang L, Scorsone KA, Liu Y, Zage PE. PMID: 26925841; PMCID: PMC4772351.
      View in: PubMed   Mentions: 28     Fields:    Translation:HumansCells
    27. Neuroblastoma patient outcomes, tumor differentiation, and ERK activation are correlated with expression levels of the ubiquitin ligase UBE4B. Genes Cancer. 2016 Jan; 7(1-2):13-26. Woodfield SE, Guo RJ, Liu Y, Major AM, Hollingsworth EF, Indiviglio S, Whittle SB, Mo Q, Bean AJ, Ittmann M, Lopez-Terrada D, Zage PE. PMID: 27014418; PMCID: PMC4773702.
      View in: PubMed   Mentions: 9  
    28. Sensitivity of neuroblastoma to the novel kinase inhibitor cabozantinib is mediated by ERK inhibition. Cancer Chemother Pharmacol. 2015 Nov; 76(5):977-87. Zhang L, Scorsone K, Woodfield SE, Zage PE. PMID: 26407819.
      View in: PubMed   Mentions: 19     Fields:    Translation:HumansAnimalsCells
    29. CD114 Expression Mediates Melanoma Tumor Cell Growth and Treatment Resistance. Anticancer Res. 2015 Jul; 35(7):3787-92. Zhang L, Agarwal S, Shohet JM, Zage PE. PMID: 26124323.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCells
    30. mTOR ATP-competitive inhibitor INK128 inhibits neuroblastoma growth via blocking mTORC signaling. Apoptosis. 2015 Jan; 20(1):50-62. Zhang H, Dou J, Yu Y, Zhao Y, Fan Y, Cheng J, Xu X, Liu W, Guan S, Chen Z, shi Y, Patel R, Vasudevan SA, Zage PE, Zhang H, Nuchtern JG, Kim ES, Fu S, Yang J. PMID: 25425103; PMCID: PMC4593396.
      View in: PubMed   Mentions: 30     Fields:    Translation:HumansAnimalsCells
    31. The novel kinase inhibitor EMD1214063 is effective against neuroblastoma. Invest New Drugs. 2014 Oct; 32(5):815-24. Scorsone K, Zhang L, Woodfield SE, Hicks J, Zage PE. PMID: 24832869.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansAnimalsCells
    32. Etoposide-loaded immunoliposomes as active targeting agents for GD2-positive malignancies. Cancer Biol Ther. 2014 Jul; 15(7):851-61. Brown BS, Patanam T, Mobli K, Celia C, Zage PE, Bean AJ, Tasciotti E. PMID: 24755919; PMCID: PMC4100986.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansCells
    33. Congenital neuroblastoma in a neonate with isotretinoin embryopathy. J Pediatr Hematol Oncol. 2014 Mar; 36(2):e75-7. Aguilar S, Louis C, Hicks J, Zage P, Russell H. PMID: 23652876.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    34. Validation of a prognostic multi-gene signature in high-risk neuroblastoma using the high throughput digital NanoString nCounter™ system. Mol Oncol. 2014 May; 8(3):669-78. Stricker TP, Morales La Madrid A, Chlenski A, Guerrero L, Salwen HR, Gosiengfiao Y, Perlman EJ, Furman W, Bahrami A, Shohet JM, Zage PE, Hicks MJ, Shimada H, Suganuma R, Park JR, So S, London WB, Pytel P, Maclean KH, Cohn SL. PMID: 24560446; PMCID: PMC4004665.
      View in: PubMed   Mentions: 20     Fields:    Translation:Humans
    35. UBE4B protein couples ubiquitination and sorting machineries to enable epidermal growth factor receptor (EGFR) degradation. J Biol Chem. 2014 Jan 31; 289(5):3026-39. Sirisaengtaksin N, Gireud M, Yan Q, Kubota Y, Meza D, Waymire JC, Zage PE, Bean AJ. PMID: 24344129; PMCID: PMC3908433.
      View in: PubMed   Mentions: 29     Fields:    Translation:HumansCells
    36. UBE4B levels are correlated with clinical outcomes in neuroblastoma patients and with altered neuroblastoma cell proliferation and sensitivity to epidermal growth factor receptor inhibitors. Cancer. 2013 Feb 15; 119(4):915-23. Zage PE, Sirisaengtaksin N, Liu Y, Gireud M, Brown BS, Palla S, Richards KN, Hughes DP, Bean AJ. PMID: 22990745; PMCID: PMC3527637.
      View in: PubMed   Mentions: 24     Fields:    Translation:HumansCells
    37. New aspects of neuroblastoma treatment: ASPHO 2011 symposium review. Pediatr Blood Cancer. 2012 Jul 01; 58(7):1099-105. Zage PE, Louis CU, Cohn SL. PMID: 22378620; PMCID: PMC4104176.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    38. Treatment of recurrent diffuse intrinsic pontine glioma: the MD Anderson Cancer Center experience. J Neurooncol. 2012 Jan; 106(2):391-7. Wolff JE, Rytting ME, Vats TS, Zage PE, Ater JL, Woo S, Kuttesch J, Ketonen L, Mahajan A. PMID: 21858608; PMCID: PMC3990187.
      View in: PubMed   Mentions: 33     Fields:    Translation:Humans
    39. Notch pathway activation induces neuroblastoma tumor cell growth arrest. Pediatr Blood Cancer. 2012 May; 58(5):682-9. Zage PE, Nolo R, Fang W, Stewart J, Garcia-Manero G, Zweidler-McKay PA. PMID: 21744479; PMCID: PMC3264695.
      View in: PubMed   Mentions: 26     Fields:    Translation:HumansCells
    40. Retinoic acid induces REST degradation and neuronal differentiation by modulating the expression of SCF(β-TRCP) in neuroblastoma cells. Cancer. 2011 Nov 15; 117(22):5189-202. Singh A, Rokes C, Gireud M, Fletcher S, Baumgartner J, Fuller G, Stewart J, Zage P, Gopalakrishnan V. PMID: 21523764.
      View in: PubMed   Mentions: 31     Fields:    Translation:HumansCells
    41. Gonadotropin-dependent precocious puberty: neoplastic causes and endocrine considerations. Int J Pediatr Endocrinol. 2011; 2011:184502. Stephen MD, Zage PE, Waguespack SG. PMID: 21603196; PMCID: PMC3212801.
      View in: PubMed   Mentions: 15  
    42. The selective Trk inhibitor AZ623 inhibits brain-derived neurotrophic factor-mediated neuroblastoma cell proliferation and signaling and is synergistic with topotecan. Cancer. 2011 Mar 15; 117(6):1321-91. Zage PE, Graham TC, Zeng L, Fang W, Pien C, Thress K, Omer C, Brown JL, Zweidler-McKay PA. PMID: 20960503.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansAnimalsCells
    43. The combination of the novel glycolysis inhibitor 3-BrOP and rapamycin is effective against neuroblastoma. Invest New Drugs. 2012 Feb; 30(1):191-9. Levy AG, Zage PE, Akers LJ, Ghisoli ML, Chen Z, Fang W, Kannan S, Graham T, Zeng L, Franklin AR, Huang P, Zweidler-McKay PA. PMID: 20890785; PMCID: PMC4831635.
      View in: PubMed   Mentions: 24     Fields:    Translation:HumansAnimalsCells
    44. Chromatin remodelling at the topoisomerase II-beta promoter is associated with enhanced sensitivity to etoposide in human neuroblastoma cell lines. Eur J Cancer. 2010 Oct; 46(15):2771-80. Das CM, Zage PE, Taylor P, Aguilera D, Wolff JE, Lee D, Gopalakrishnan V. PMID: 20886683; PMCID: PMC3025305.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCells
    45. Signaling of ERBB receptor tyrosine kinases promotes neuroblastoma growth in vitro and in vivo. Cancer. 2010 Jul 01; 116(13):3233-43. Richards KN, Zweidler-McKay PA, Van Roy N, Speleman F, Trevino J, Zage PE, Hughes DP. PMID: 20564646; PMCID: PMC2923448.
      View in: PubMed   Mentions: 21     Fields:    Translation:HumansAnimalsCells
    46. A novel therapeutic combination for neuroblastoma: the vascular endothelial growth factor receptor/epidermal growth factor receptor/rearranged during transfection inhibitor vandetanib with 13-cis-retinoic acid. Cancer. 2010 May 15; 116(10):2465-75. Zage PE, Zeng L, Palla S, Fang W, Nilsson MB, Heymach JV, Zweidler-McKay PA. PMID: 20225331.
      View in: PubMed   Mentions: 20     Fields:    Translation:HumansAnimalsCells
    47. Multiple receptor tyrosine kinases regulate HIF-1alpha and HIF-2alpha in normoxia and hypoxia in neuroblastoma: implications for antiangiogenic mechanisms of multikinase inhibitors. Oncogene. 2010 May 20; 29(20):2938-49. Nilsson MB, Zage PE, Zeng L, Xu L, Cascone T, Wu HK, Saigal B, Zweidler-McKay PA, Heymach JV. PMID: 20208561.
      View in: PubMed   Mentions: 38     Fields:    Translation:HumansAnimals
    48. Identification and preclinical characterization of AZ-23, a novel, selective, and orally bioavailable inhibitor of the Trk kinase pathway. Mol Cancer Ther. 2009 Jul; 8(7):1818-27. Thress K, Macintyre T, Wang H, Whitston D, Liu ZY, Hoffmann E, Wang T, Brown JL, Webster K, Omer C, Zage PE, Zeng L, Zweidler-McKay PA. PMID: 19509272.
      View in: PubMed   Mentions: 24     Fields:    Translation:HumansAnimalsCells
    49. Outcomes of the POG 9340/9341/9342 trials for children with high-risk neuroblastoma: a report from the Children's Oncology Group. Pediatr Blood Cancer. 2008 Dec; 51(6):747-53. Zage PE, Kletzel M, Murray K, Marcus R, Castleberry R, Zhang Y, London WB, Kretschmar C, Children's Oncology Group. PMID: 18704922; PMCID: PMC4426094.
      View in: PubMed   Mentions: 22     Fields:    Translation:Humans
    50. Outcomes of a two-drug chemotherapy regimen for intraocular retinoblastoma. Pediatr Blood Cancer. 2008 Mar; 50(3):567-72. Zage PE, Reitman AJ, Seshadri R, Weinstein JL, Mets MB, Zeid JL, Greenwald MJ, Strauss LC, Goldman S. PMID: 17729249.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCTClinical Trials
    51. Measuring cytotoxicity: a new perspective on LC50. Anticancer Res. 2007 Jan-Feb; 27(1A):35-8. Zhang M, Aguilera D, Das C, Vasquez H, Zage P, Gopalakrishnan V, Wolff J. PMID: 17352213.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCells
    52. Predicting tumor cell repopulation after response: mathematical modeling of cancer cell growth. Anticancer Res. 2006 Jul-Aug; 26(4B):2933-6. Zhang M, Das C, Vasquez H, Aguilera D, Zage PE, Gopalakrishnan V, Wolff JE. PMID: 16886616.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    53. SPARC expression is associated with impaired tumor growth, inhibited angiogenesis and changes in the extracellular matrix. Int J Cancer. 2006 Jan 15; 118(2):310-6. Chlenski A, Liu S, Guerrero LJ, Yang Q, Tian Y, Salwen HR, Zage P, Cohn SL. PMID: 16052522.
      View in: PubMed   Mentions: 41     Fields:    Translation:HumansAnimalsCells
    54. Cross-talk between Schwann cells and neuroblasts influences the biology of neuroblastoma xenografts. Am J Pathol. 2005 Mar; 166(3):891-900. Liu S, Tian Y, Chlenski A, Yang Q, Zage P, Salwen HR, Crawford SE, Cohn SL. PMID: 15743800; PMCID: PMC1602341.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansAnimalsCells
    55. Association of epigenetic inactivation of RASSF1A with poor outcome in human neuroblastoma. Clin Cancer Res. 2004 Dec 15; 10(24):8493-500. Yang Q, Zage P, Kagan D, Tian Y, Seshadri R, Salwen HR, Liu S, Chlenski A, Cohn SL. PMID: 15623630.
      View in: PubMed   Mentions: 30     Fields:    Translation:HumansCells
    56. Integrins interact with focal adhesions through multiple distinct pathways. J Cell Physiol. 1999 Oct; 181(1):74-82. David FS, Zage PE, Marcantonio EE. PMID: 10457355.
      View in: PubMed   Mentions: 8     Fields:    Translation:AnimalsCells
    57. The membrane proximal region of the integrin beta cytoplasmic domain can mediate oligomerization. Cell Adhes Commun. 1998 Jul; 5(5):335-47. Zage PE, Marcantonio EE. PMID: 9789682.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansAnimalsCells